Cargando…

Does Combination Therapy With SGLT2 Inhibitors and Renin–Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?

Detalles Bibliográficos
Autores principales:	Zhao, Li-Min, Zhang, Miao, Zhan, Ze-Lin, Qiu, Mei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131654/ https://www.ncbi.nlm.nih.gov/pubmed/34026878 http://dx.doi.org/10.3389/fcvm.2021.679124

Ejemplares similares

Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM
por: Li, Lu-Feng, et al.
Publicado: (2021)

Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology
por: Wang, Anzhu, et al.
Publicado: (2022)

Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases
por: Sharma, Ravindra K., et al.
Publicado: (2021)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

Renin-angiotensin system blockers and COVID-19
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2021)

Class effects of SGLT2 inhibitors on cardiorenal outcomes
por: Kluger, Aaron Y., et al.
Publicado: (2019)

Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
por: Hou, Yi-Chou, et al.
Publicado: (2020)

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
por: Salvatore, Teresa, et al.
Publicado: (2022)

Role and Mechanism of the Renin-Angiotensin-Aldosterone System in the Onset and Development of Cardiorenal Syndrome
por: Ma, Kexin, et al.
Publicado: (2022)

Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
por: Farid fahmy, Sarah, et al.
Publicado: (2023)

Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Biochemical monitoring after initiation of aldosterone antagonist therapy in users of renin–angiotensin system blockers: a UK primary care cohort study
por: Sinnott, Sarah-Jo, et al.
Publicado: (2017)

Renin-Angiotensin-Aldosterone System Blockers Are Not Associated With Coronavirus Disease 2019 (COVID-19) Hospitalization: Study of 1,439 UK Biobank Cases
por: Raisi-Estabragh, Zahra, et al.
Publicado: (2020)

Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2
por: Lévy, Bernard I., et al.
Publicado: (2020)

Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
por: Jiang, Xiao, et al.
Publicado: (2020)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes
por: An, Jaejin, et al.
Publicado: (2023)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020)

Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
por: Zhao, Li-Min, et al.
Publicado: (2022)

Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming
por: Gao, Yue-Ming, et al.
Publicado: (2022)

COVID and the Renin-Angiotensin System: Are Hypertension or Its Treatments Deleterious?
por: Zores, Florian, et al.
Publicado: (2020)

Effect of a SGLT2 inhibitor on the systemic and intrarenal renin–angiotensin system in subtotally nephrectomized rats
por: Li, Lei, et al.
Publicado: (2017)

Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Inflammatory Response and Viral Clearance in COVID-19 Patients
por: Huang, Linna, et al.
Publicado: (2021)

SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules
por: Wang, Yajiao, et al.
Publicado: (2023)

SGLT2 Inhibitor–Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection
por: Herat, Lakshini Y., et al.
Publicado: (2020)

Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?
por: Verma, Subodh
Publicado: (2020)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
por: Brown, Emily, et al.
Publicado: (2021)

Association of Renin-Angiotensin System Blockers With Outcomes in Patients with COVID-19
por: Garg, Aakash, et al.
Publicado: (2020)

Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study
por: Cesaro, Arturo, et al.
Publicado: (2022)

Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review
por: Mascolo, Annamaria, et al.
Publicado: (2020)

Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study
por: Schmidt, Morten, et al.
Publicado: (2017)

SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D
por: Escalada, Javier
Publicado: (2022)

Chronic effects of lead on the renin-angiotensin system.
por: Vander, A J
Publicado: (1988)

A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors
por: Siragy, Helmy M
Publicado: (2011)

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
por: Heerspink, H. J. L., et al.
Publicado: (2016)

Renin-angiotensin system blockers regulate the metabolism of isolated fat cells in vitro
por: Caminhotto, R de O., et al.
Publicado: (2016)

In reply— Association of Renin-Angiotensin System Blockers with Outcomes in Patients With COVID-19
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Impact of renin-angiotensin system inhibitors and beta-blockers on dental implant stability
por: Saravi, Babak, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j7ect72dqlhegl5envplq9e5gg